Clinical Trials
17 trialsNCT03433183 2026-05-27
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03581487 2025-11-05
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01256359 2024-08-15
DOC-MEK
University of Oxford
Phase 2 Completed
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT03326388 2024-04-04
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 1/2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT02768766 2023-08-31
Intermittent Selumetinib for Uveal Melanoma
Columbia University
Phase 1 Completed
NCT02503358 2023-03-21
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01146756 2023-02-15
MEKRT
The Christie NHS Foundation Trust
Phase 1 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT01160718 2019-05-15
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Swiss Cancer Institute
Phase 2 Completed
NCT02025114 2018-07-10
Selumetinib in Combination With Gefitinib in NSCLC Patients
National Taiwan University Hospital
Phase 1/2 Completed
NCT00970359 2017-04-12
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01313039 2017-02-07
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
University of Miami
Phase EARLY_PHASE1 Completed
NCT01242605 2016-05-13
ABC-04
University College, London
Phase 1 Completed